Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H27N5O4.ClH |
Molecular Weight | 425.91 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N(C)CCCNC(=O)C3CCCO3
InChI
InChIKey=YTNKWDJILNVLGX-UHFFFAOYSA-N
InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
Molecular Formula | C19H27N5O4 |
Molecular Weight | 389.4488 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the
signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9556192
Curator's Comment: Alfuzosin does not penetrate the blood–brain barrier well
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
8.0 null [pKi] | |||
8.0 null [pKi] | |||
8.5 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | UROXATRAL Approved UseUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. (1) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. (1.1) UROXATRAL is not indicated for use in the pediatric population. (1.1, 8.4, 12.3) 1.1 Important Limitations of Use UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population. Launch Date1.05537602E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.6 ng/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
194 ng × h/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Other AEs: Dizziness, Headache... Other AEs: Dizziness (8.9%) Sources: Headache (6.7%) Malaise (2%) |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Disc. AE: Abdominal pain, Diarrhoea... AEs leading to discontinuation/dose reduction: Abdominal pain (grade 1-2, 1.1%) Sources: Diarrhoea (grade 1-2, 1.1%) Dizziness (grade 1-2, 3.2%) Headache (grade 1-2, 1.1%) Ventricular fibrillation (grade 1-2, 1.1%) |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Disc. AE: Vertigo, Syncope... AEs leading to discontinuation/dose reduction: Vertigo (1.35%) Sources: Syncope (0.55%) Postural hypotension (0.42%) Headache (0.39%) Nausea (0.46%) Abdominal pain (0.35%) Diarrhoea (0.16%) CNS disorder (NOS) (0.14%) Asthenia (0.19%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Malaise | 2% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Headache | 6.7% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Dizziness | 8.9% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Abdominal pain | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Diarrhoea | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Headache | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Ventricular fibrillation | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Dizziness | grade 1-2, 3.2% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
CNS disorder (NOS) | 0.14% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Diarrhoea | 0.16% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Asthenia | 0.19% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Abdominal pain | 0.35% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Headache | 0.39% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Postural hypotension | 0.42% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Nausea | 0.46% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Syncope | 0.55% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Vertigo | 1.35% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: administration with ketoconazole increased alfuzosin Cmax and AUClast by, 2.3-fold and 3.2 fold, respectively; administration with diltiazem increased Cmax and AUC0-24 of alfuzosin 1.5-fold and 1.3-fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_BioPharmr_P1.pdf#page=34 Page: 34.0 |
|||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_Pharmr_P1.pdf#page=27 Page: 27,28 |
PubMed
Title | Date | PubMed |
---|---|---|
Initial choices and final outcomes in lower urinary tract symptoms. | 2001 |
|
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. | 2001 |
|
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. | 2001 Dec |
|
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. | 2001 Dec |
|
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors. | 2001 Jan |
|
[Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)]. | 2001 Jan-Feb |
|
The efficacy and safety of a new once-a-day formulation of an alpha-blocker. | 2001 Mar |
|
Does acute urinary retention respond to alpha-blockers alone? | 2001 Mar |
|
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. | 2002 |
|
Tamsulosin: an update of its role in the management of lower urinary tract symptoms. | 2002 |
|
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. | 2002 Dec 12 |
|
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. | 2002 Jan |
|
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. | 2002 Jul |
|
Gateways to clinical trials. | 2002 Oct |
|
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. | 2002 Oct |
|
Use of alpha-blockers and the risk of hip/femur fractures. | 2003 Dec |
|
Benign prostatic hyperplasia. | 2003 Feb |
|
The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. | 2003 Feb |
|
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. | 2003 Jul 15 |
|
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. | 2003 Jun 17 |
|
Estimated costs of treatment of benign prostate hyperplasia in Brazil. | 2003 May-Jun |
|
Alfuzosin for the management of benign prostate hyperplasia. | 2003 Nov |
|
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. | 2004 |
|
Drug approval highlights for 2003. | 2004 Feb |
|
Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats. | 2004 Jan |
|
[Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?]. | 2004 Jan-Mar |
|
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders]. | 2004 Jul |
|
On call. My doctor gave me a prescription for Uroxatral to treat my enlarged prostate. I tried to look up this medicine in your Harvard Medical School Guide to Men's Health, but I couldn't find it. What can you tell me about Uroxatral? | 2004 Jun |
|
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. | 2004 Mar |
|
Patients with bladder outlet obstruction who refuse treatment show no clinical and urodynamic change after long-term follow-up. | 2004 Mar |
|
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. | 2004 Mar |
|
New drugs of 2003. | 2004 Mar-Apr |
|
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. | 2004 Nov |
|
Delayed complications of discontinuation of intrathecal baclofen therapy: resurgence of dyssynergic voiding, which triggered off autonomic dysreflexia and hydronephrosis. | 2004 Oct |
|
New drugs 04. Part III. | 2004 Sep |
|
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease. | 2004 Sep |
|
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. | 2005 Apr |
|
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. | 2005 Aug |
|
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. | 2005 Jan |
|
[The role of alpha1-adrenoblocker alfuzosine in diagnostic-therapeutic algorithm of hyperactive urinary bladder management in women and selection of patients for treatment with M-cholinergic antagonists]. | 2005 Jan-Feb |
|
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. | 2005 Jul |
|
Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. | 2005 Jun |
|
The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. | 2005 Mar |
|
The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. | 2005 Mar |
|
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. | 2005 May |
|
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. | 2005 Nov |
|
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. | 2005 Oct |
|
A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. | 2005 Sep-Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/alfuzosin.html
Usual Adult Dose for Benign Prostatic Hyperplasia
Extended-release tablet: 10 mg orally once a day immediately after the same meal each day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428174
In organ baths, isolated prostatic strips and isolated bladder strips were incubated with vehicle, tadalafil (10⁻⁶ M and 10⁻⁵ M), alfuzosin (3×10⁻⁸ M or 10⁻⁶ M and 10⁻⁵ M) or a combination. Concentration-response curves (CRCs) to norepinephrine were generated on prostatic strips and detrusor strips precontracted with carbachol. Strips were also submitted to electrical field stimulation (EFS). When alfuzosin and tadalafil were combined, the maximal relaxation to norepinephrine on carbachol-precontracted detrusor strips was significantly increased compared with tadalafil alone, and EFS-induced detrusor contractions were better inhibited compared with each compound alone. Tadalafil significantly inhibited norepinephrine-induced prostatic strip contractions by reducing the maximal effect, whereas alfuzosin shifted the CRC of norepinephrine to the right. Combining both tadalafil and alfuzosin resulted in a greater relaxant effect.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 18:46:52 UTC 2022
by
admin
on
Sat Dec 17 18:46:52 UTC 2022
|
Record UNII |
75046A1XTN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C53408
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
NN-27
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
75046A1XTN
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
DBSALT001063
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
75046A1XTN
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
81403-68-1
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
DTXSID3045514
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
SUB00340MIG
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
46043
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | RxNorm | ||
|
1012917
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
CHEMBL709
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
71764
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | |||
|
M1501
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY | Merck Index | ||
|
32286
Created by
admin on Sat Dec 17 18:46:52 UTC 2022 , Edited by admin on Sat Dec 17 18:46:52 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |